drug access
Recently Published Documents


TOTAL DOCUMENTS

153
(FIVE YEARS 15)

H-INDEX

17
(FIVE YEARS 1)

2021 ◽  
Vol 29 (12) ◽  
pp. 1774-1787.e9 ◽  
Author(s):  
Paolo Mesén-Ramírez ◽  
Bärbel Bergmann ◽  
Mourad Elhabiri ◽  
Lei Zhu ◽  
Heidrun von Thien ◽  
...  


Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1980
Author(s):  
Rory Whelan ◽  
Grainne C. Hargaden ◽  
Andrew J. S. Knox

The highly secure blood–brain barrier (BBB) restricts drug access to the brain, limiting the molecular toolkit for treating central nervous system (CNS) diseases to small, lipophilic drugs. Development of a safe and effective BBB modulator would revolutionise the treatment of CNS diseases and future drug development in the area. Naturally, the field has garnered a great deal of attention, leading to a vast and diverse range of BBB modulators. In this review, we summarise and compare the various classes of BBB modulators developed over the last five decades—their recent advancements, advantages and disadvantages, while providing some insight into their future as BBB modulators.



2021 ◽  
pp. 151-172
Author(s):  
Florence Allain ◽  
Ndeye Aissatou Ndiaye ◽  
Anne-Noël Samaha


2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Brooke E. Wilson ◽  
David W. Cescon


2021 ◽  
Author(s):  
Tristan E. Knight ◽  
Yubin Ge ◽  
Jeffrey W. Taub ◽  
Johann Hitzler ◽  
Joerg Krueger
Keyword(s):  


Author(s):  
Arnaud Bayle ◽  
Antoine Hollebecque ◽  
Barbara Pistilli ◽  
Christophe Massard ◽  
Aurélien Marabelle


Sign in / Sign up

Export Citation Format

Share Document